Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Response to Congress on CURES 2.0 Request for Input
-
ACMG Comments to CMS about Proposed Decision for Medicare Coverage of NGS for Advanced Cancer
-
ACMG & ASHG Presidents’ Sign-on Letter to Congress Concerning Patent Eligibility Reform
-
Group Sign-on Letter to Congress Opposing Proposed Amendments to Section 101 of the Patent Act
-
ACMG Comments to CMS Regarding NCD 90.2 and Medicare Coverage of NGS for Advanced Cancer
-
Group Sign-on Letter to CMS Requesting Extension of Comment Period Regarding NGS Coverage Reconsideration
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
Group Sign-on Letter to CMS Requesting Revision of Interpretation of NCD for NGS for Advanced Cancer
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)